Document:

<PAGE>   1

                                                                  EXHIBIT 10(OO)

                                    2000-2002
                       BFGOODRICH LONG-TERM INCENTIVE PLAN

                 THIS DOCUMENT CONSTITUTES PART OF A PROSPECTUS
             COVERING SECURITIES THAT HAVE BEEN REGISTERED UNDER THE
                             SECURITIES ACT OF 1933.

Name:

AWARD GRANT

You have been granted the following Long-Term Incentive Plan shares for the
three-year performance period 2000 through 2002:

            ________ phantom Performance Shares

Grants are credited as phantom Performance Shares in a book account for you.
Each phantom Performance Share will be equivalent to one share of BFGoodrich
common stock.

PLAN GOALS

The number of phantom Performance Shares you earn will depend on the three-year
performance of the total Company, as measured against performance goals for the
Company and each segment to be communicated to participants by Supplement.

OTHER IMPORTANT INFORMATION

-    Grants will be credited as phantom Performance Shares in a book account for
     you. Each phantom Performance Share will be equivalent to one share of
     BFGoodrich common stock.

-    Dividend equivalents will be accrued on all phantom Performance Shares in
     your account during the Plan cycle. Such dividend equivalents will be
     credited to your account in the form of additional phantom Performance
     Shares at the same time and in the same amount as actual dividend payments
     on BFGoodrich common stock.

-    You will not earn any phantom Performance Shares if the Company's
     performance during the 2000 - 2002 period is below threshold performance.

<PAGE>   2

-    If threshold performance is achieved, the number of shares to be received
     free of further restrictions will range from 0% to 200% of your total
     phantom Performance Share account (including shares credited through
     dividend equivalents), based on attainment against goals set by the
     Compensation Committee.

-    Payments from the Plan, if any, at the end of the Plan cycle, will be made
     in actual shares of BFG common stock, less the number of shares to satisfy
     applicable withholding taxes.

-    New phantom Performance Share grants and performance targets are expected
     to be established for another three-year Plan cycle beginning in 2001.

-    If you become totally disabled under the Company's Long-Term Disability
     Plan, or retire under the Company's Retirement Program for Salaried
     Employees during the Plan cycle, you will receive a pro rata payout at the
     end of the Plan cycle, based upon the time portion of the cycle during
     which you were employed. The actual payout will not occur until after the
     end of the Plan cycle, at which time the financial performance for the
     entire Plan cycle will be used to determine the size of the award in that
     event.

-    If you die during a Plan cycle, you will receive a pro rata payout of your
     account, based upon financial results calculated for the portion of the
     cycle through the end of the fiscal quarter following your death.

-    If you terminate employment prior to the end of the Plan cycle for reasons
     other than death, disability or retirement, you will forfeit all
     Performance Shares.

-    The Compensation Committee of the Board of Directors retains the right in
     its sole discretion to reduce any award which would otherwise be payable,
     unless there has been a Change in Control, as defined in the Stock Option
     Plan.

-    Any income you derive from a payout of Performance Shares will not be
     considered eligible earnings for Company or subsidiary pension plans,
     savings plans, profit sharing plans or other benefit plans.

FOR MORE INFORMATION

If you have questions about the Long-Term Incentive Plan or need additional
information, contact Kevin Heslin at (704) 423-7094.

                                       2<PAGE>   1
                                                                    EXHIBIT 10.1

              AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AGREEMENT

     This This AMENDMENT TO PATENT AND TECHNOLOGY LICENSE AGREEMENT
("Amendment") is made and entered into as of this 9th day of June, 2000 by and
between ACCUMED INTERNATIONAL, INC., a Delaware corporation ("AccuMed") and
AMPERSAND MEDICAL CORPORATION ("Ampersand" or "Licensee"), a Delaware
corporation, as Assignee of INPATH, LLC. ("Inpath"), a wholly owned subsidiary
of Ampersand.

     WHEREAS, as of September 4, 1998 AccuMed and Inpath entered into that
certain Patent and Technology Licence Agreement (the "License Agreement").

     WHEREAS, on November 19, 1999 Inpath purported to terminate the License
Agreement.

     WHEREAS, AccuMed challenged the validity of the November 19, 1999
termination of the License Agreement by Inpath.

     WHEREAS, on March 29, 2000 the parties hereto entered into a Letter
Agreement ("Letter Agreement") pursuant to which the parties agreed to resolve
all differences among them as set forth in the Letter Agreement and in this
Amendment, the Assignment and the related Additional License and Purchase
Agreement described therein.

     WHEREAS, in conjunction with this Amendment, Inpath has assigned all of its
rights, title, interest and obligations under the License Agreement and this
Amendment to Ampersand.

     WHEREAS, pursuant to the Letter Agreement, AccuMed agreed to the Assignment
of the License Agreement by Inpath to Ampersand.

     NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, AccuMed and Ampersand hereby agree as follows:

     1. Definitions. The capitalized terms used in this Amendment shall have the
respective meanings ascribed to them in the License Agreement unless otherwise
expressly defined in this Amendment.

     2. Reinstatement of License Agreement. AccuMed and Ampersand agree to
reinstate and modify the September 4, 1998 License Agreement as set forth
herein.

     3. The following definitions outlined in the License Agreement are hereby
replaced with the following:

     "Foreign Patents" means, collectively (i) the letters patent corresponding
     to the U.S. Patents, issued or applied for in a country other than the
     United States; (ii) the continuations, continuations-in-part, or divisions
     thereof; and (iii) any and all improvements,

<PAGE>   2

     modifications, extensions, renewals, or reissues of such Patent, subject to
     the provisions of Section 5.1 governing the prosecution thereof.

     "Sales" means all recorded booked revenues for actual sales upon which
     payment has been collected by Licensee or an Affiliated Person of Licensee
     (whether in cash or by way of other benefit, advantage, or concession (in
     which case the applicable revenue will be the monetary equivalent or value
     of same).

     "U.S. Patents" means (i) AccuMed's Patent entitled "A Method and Apparatus
     For Imaging and Sampling Diseased Tissue Using Autofluorescence" U.S.
     patent number 5,999,844 dated 12/07/99; (ii) the continuations,
     continuations-in-part or divisions thereof, if any; and (iii) any and all
     improvements, modifications, extensions, renewals or reissues of such
     Patent, if any.

     4. Section 2.1 of the License Agreement is replaced with the following:

     2.1 Grant of License in Patents. AccuMed hereby grants to Licensee, and
     Licensee accepts from AccuMed, an exclusive, non-transferable (except as
     provided in Section 10.8 herein), non-divisible license to make, have made,
     use, offer to sell and sell Licensed Products covered by the U.S. Patents
     and Foreign Patents for use in cervical and ovarian gynecological
     applications for Point of Care and concurrent with a patient's medical
     office visit in a physician's office and the non-exclusive license to make,
     have made, use, offer to sell and sell Licensed Products covered by the
     U.S. Patents and Foreign Patents for use in cervical and ovarian
     gynecological applications for Point of Care in labs outside of the
     physician's office.

     5. Section 2.2 of the License Agreement is replaced with the following:

     2.2 Grant of License in Technology. AccuMed hereby grants to Licensee, and
     Licensee accepts from AccuMed, and exclusive, non-transferable (except as
     provided in Section 10.8 herein), non-divisible license to make, have made,
     use, offer to sell and sell Licensed Products utilizing the Technology for
     use in cervical and ovarian gynecological applications for Point of Care
     and concurrent with a patient's medical office visit in a physician's
     office and the non-exclusive license to make, have made, use, offer to sell
     and sell Licensed Products utilizing the Technology for use in cervical and
     ovarian gynecological applications for Point of Care in labs outside of the
     physician's office.

     6. The following sentence is added to the end of Section 2.5:

          "The parties acknowledge and agree that AccuMed has no obligation,
          express or implied, to (i) develop any improvements to the U.S.
          Patents, the Foreign Patents, the Technology on the Copyrighted Works
          or (ii) to file any patent applications for any further developments,
          inventions or discoveries known to AccuMed.

                                       2
<PAGE>   3

     7. Section 2.6 of the License Agreement is stricken in its entirety.

     8. Section 3.1 of the License Agreement is modified to add the following
sentence:

     As of the date of the Amendment hereto, all of the Guaranteed License Issue
Fees due to be paid hereunder have been paid and no further amounts are
outstanding.

     9. Section 3.2 of the License Agreement is replaced with the following:

     3.2  Required Royalty; Minimum Guaranteed Payments; Advanced Required
          Royalty Payments.

          (a) For the rights and privileges granted to Licensee under this
          Agreement, Licensee (subject to paragraph (b) of Section 5.1, Section
          5.2, and Section 5.3) shall pay to AccuMed from and after January 1,
          2000 until the licenses hereunder are terminated in accordance with
          this Agreement, a royalty rate equal to 4% of all Sales ("Required
          Royalty").

          (b) Notwithstanding the amount of any sales or Required Royalty,
          Licensee shall pay AccuMed, a minimum guaranteed payment of $5,000,000
          ("Minimum Guaranteed Payment") payable by Licensee only out of the
          booked revenues for Sales at the Royalty Rate outlined in (a) herein
          as Required Royalty Payments for the term of the Agreement. In the
          event that the Minimum Guaranteed Payment of $5,000,000 is not paid in
          full at the time of the termination of this Agreement, then the
          difference between the amounts actually paid by Licensee to AccuMed as
          Required Royalty Payments and $5,000,000 shall be immediately due and
          payable by Licensee to AccuMed.

          (c) Upon the signing by all parties of the Amendment, and related
          documents, Licensee shall pay or provide to AccuMed the following:

          (i) $500,000 in cash, which cash payment shall represent an advanced,
          non-refundable Required Royalty Payment hereunder;

          (ii) a $100,000 convertible promissory note payable to AccuMed (with
          conversion rights at $3.50/share into registered shares of Ampersand)
          bearing interest of 11% and due or convertible on March 29, 2001. The
          principal amount of the note shall represent an additional advanced,
          non-refundable Required Royalty Payment hereunder; and

          (iii) 128,571 shares of Ampersand common stock which stock Ampersand
          will price protect to a share price of not less than $3.50/share to a
          measurement date sixty days following the date on which the shares
          being issued become registered and are freely

                                       3
<PAGE>   4

          tradable. If the market price at the measurement date is less than
          $3.50 per share, Ampersand shall at its option (x) make a cash payment
          to AccuMed in an amount representing the difference in market price
          and $3.50 per share multiplied by 128,571 shares or (y) issue an
          additional number of Ampersand shares to AccuMed which number shall be
          arrived at by multiplying the difference in the then market price per
          share and $3.50 and dividing the resultant sum by the then market
          price per share. The issuance of common stock by Ampersand to AccuMed
          as outlined herein, to a value of $450,000, shall represent an
          additional advanced, non-refundable Required Royalty Payment
          hereunder.

          (d) The cash payments and issuance of stock outlined in (c)(i) - (iii)
          herein represent the payment by Licensee of advanced Required Royalty
          Payments to AccuMed. Ampersand shall not be required to make any
          additional payments to AccuMed for Required Royalty Payments until the
          total of the Required Royalty Payments called for hereunder from
          Ampersand, exceeds the amount of advanced Required Royalty Payments
          actually made by Ampersand to AccuMed pursuant to paragraphs
          c(i)-(iii) herein.

          (e) The shares of Ampersand stock to be issued to AccuMed herein shall
          be registered with an appropriate Registration Statement (excluding
          the S-8 underlying the Employee Equity Incentive Plan) which is
          presently being prepared by Ampersand. AccuMed will not be subject to
          any restrictions in the disposal of shares it holds, other than those
          regarding unregistered shares prior to the effective date of the
          Registration Statement outlined herein and those imposed by applicable
          securities laws.

     10. Paragraph 5.1 of the License Agreement is replaced with the following:

          5.1 Prosecution and Protection.

               (a) AccuMed shall have the authority, in its discretion, but no
          duty to prosecute the application for the issuance of Foreign Patents.
          If AccuMed shall elect to prosecute a Foreign Patent under this
          Section, it shall be at the sole cost and expense of AccuMed.

               (b) Licensee shall notify AccuMed in writing of Licensee's sale
          of Licensed Products in any Foreign Country upon or prior to the date
          on which Licensee first sells Licensed Products in such Foreign
          Country. If a Foreign Patent shall not already be pending or issued in
          such Foreign County, AccuMed shall have twenty-one (21) days from such
          written notice to notify Licensee in writing whether or not AccuMed
          will commence the prosecution thereof. If AccuMed elects, in such
          notice, not to prosecute a Foreign Patent in such Foreign Country or
          if AccuMed fails to make a timely election, then Licensee may elect to
          prosecute such Foreign Patent, at Licensee's sole cost and expense,
          for and on behalf of and in the name of AccuMed. Licensee may deduct
          all reasonable out-of-pocket costs and expenses,

                                       4
<PAGE>   5

          including without limitation, attorneys' fees and filing costs,
          incurred by Licensee for its prosecution (in accordance its election
          under with this paragraph) of Foreign Patents in any Foreign Country
          from the Required Royalties (but not the Minimum Guaranteed Payments)
          applicable to that Foreign Country under Section 3.2. AccuMed will
          provide to Licensee all information, papers, instruments or affidavits
          required to apply for and obtain Foreign Patents in AccuMed's name and
          will provide reasonable assistance to Licensee in Licensee's efforts
          to prosecute any Foreign Patents in accordance with its election under
          this paragraph. Any such Foreign Patents prosecuted by Licensee for
          and on behalf of AccuMed shall be the sole and exclusive property of
          AccuMed, but Licensee shall be granted a license thereunder coincident
          with the grant under Section 2.1 for all Foreign Patents.

               (c) Nothing in this Section shall (i) require either AccuMed or
          Licensee to prosecute patents in any Foreign Country or (ii) as
          between the parties, restrict Licensee from exercising its exclusive
          license rights under this Agreement in any Foreign Country or
          throughout the Territory, regardless of whether Licensee or AccuMed
          elects to prosecute any application for Foreign Patents therein.

     11. Paragraph 5.2 of the License Agreement is replaced with the following:

          5.2 Infringement by Third Parties. Each party shall inform the other
          party of any infringement or suspected infringement of the Patents or
          infringement (including any misappropriation) of the Technology of
          which such party becomes aware within ten (10) business days after
          such party becomes aware of any such infringement or suspected
          infringement. For a period of thirty (30) days after receipt by
          AccuMed of, or AccuMed's sending of, such notice of infringement,
          AccuMed will have the exclusive right to commence an action and
          otherwise assert rights in the Patents and the Technology against any
          such infringers or suspected infringers and will have the right at its
          sole discretion to make any settlement or compromise with the
          third-party infringer, provided that the terms of any such settlement
          may not modify the exclusivity of the licenses granted to LICENSEE in
          this Agreement or otherwise diminish LICENSEE'S economic rights or
          expectations hereunder. If AccuMed shall elect to prosecute any such
          infringer, LICENSEE shall take such steps as are reasonably requested
          by AccuMed to enable it to protect its rights under the Patents and
          under the Technology against any such infringement or suspected
          infringement. If (i) AccuMed fails to commence an action or otherwise
          assert its rights in the Patents and the Technology against any such
          infringers or suspected infringers within such thirty (30) day period
          and (ii) LICENSEE provides AccuMed with the opinion of patent counsel
          mutually acceptable to the parties stating that there is a likelihood
          of infringement or misappropriation by such suspected infringers (an
          "Infringement Opinion"), then LICENSEE may bring an action or
          proceeding

                                       5
<PAGE>   6

          (including any alternative dispute resolution process) to enjoin the
          infringement, to recover damages for it, or both and AccuMed grants
          LICENSEE the right to use AccuMed's name in connection therewith and
          will have the right at LICENSEE'S sole discretion to make any
          settlement or compromise with the third-party infringer, in accordance
          with and subject to the provisions set forth below. If an Infringement
          Opinion is delivered to AccuMed and, accordingly, LICENSEE is
          permitted to bring such action, then LICENSEE may elect to deduct a
          percentage of its out-of-pocket costs and expenses (but otherwise will
          bear all other costs and expenses), which includes without limitation
          court costs and attorneys' fees for such action up to a maximum
          deduction of fifty percent (the "Fee Percentage") and shall notify
          AccuMed of such election and the applicable Fee Percentage when the
          Infringement Opinion is delivered by LICENSEE to AccuMed. LICENSEE
          shall be permitted to deduct from future Minimum Guaranteed Payments
          and Required Royalties, as they become due under this Agreement, that
          portion of its out-of-pocket expenses in an amount equal to the Fee
          Percentage thereof. All proceeds of any action or proceeding brought
          by LICENSEE or AccuMed (if any) shall be shared between AccuMed and
          LICENSEE pro rata in accordance with the Fee Percentage (i.e. AccuMed
          shall receive the Fee Percentage of such proceeds and LICENSEE shall
          receive the remainder). If LICENSEE shall be permitted to bring an
          action pursuant to this Section, AccuMed shall take such steps as are
          reasonably requested by LICENSEE at LICENSEE'S expense to enable it to
          protect its licensee rights under the Patents and under the Technology
          against any such infringement or suspected infringement.

     12. Section 6.3(a) of the License Agreement is replaced by the following:

               (a) Licensee Covenant. Licensee shall not, directly or
          indirectly, whether through an Affiliated Person or otherwise, until
          the termination of this Agreement, and for a period of one year
          thereafter, without the prior written approval of AccuMed, employ,
          engage, or seek to employ or engage, directly or indirectly, any
          employee of AccuMed or its subsidiaries.

     13. Paragraph 9.2 of the License Agreement is replaced by the following:

     9.2 Effect of Patent Invalidation. If any Patents shall issue and,
     thereafter, if all claims of all of the Patents should be finally
     determined to be invalid by a decision of a court of competent jurisdiction
     that is final and to which no right of appeal exists, then the rate of the
     Required Royalty shall be reduced from four percent (4%) to three and
     three-quarters percent (3.75%). Licensee acknowledges that the licenses
     hereunder in the Technology independent of any issued and valid Patent are
     valuable and reasonable consideration for the Required Royalty and Minimum
     Guaranteed Payments. Licensee shall pay (subject to paragraph (b)

                                       6

<PAGE>   7

     of Section 5.1, Section 5.2, and Section 5.3) all Required Royalties (at
     the four percent (4%) rate) due and payable before any such final
     determination of invalidity and during the pendency of any validly
     challenge, and Licensee is not entitled to any refund or credit for any
     past due Minimum Guaranteed Payments, Required Royalties, or the Guaranteed
     License Issue Fee payments. Licensee shall pay all Royalty Payments
     accruing during the pendency of any challenge to the validity of any of the
     Patents.

     14. Paragraph 9.3 of the License Agreement shall be replaced by the
following:

     9.3 Termination by Licensee. Licensee shall not be entitled to terminate
     its obligations under this Agreement until AccuMed's receipt of the Minimum
     Guaranteed Payment of $5,000,000. Thereafter, Licensee, at its election may
     (x) terminate the exclusivity of the licenses granted hereunder upon thirty
     (30) days written notice to AccuMed that in Licensee's reasonable
     determination the commercial exploitation of the Licensed Product is not
     commercially viable; or (y) terminate this Agreement in its entirety. In
     the event that Licensee terminates the exclusivity in accordance with (x)
     herein, Licensee shall continue to be obligated to make Required Royalty
     Payments. In the event that Licensee seeks to terminate this Agreement in
     its entirety, Licensee is still required to pay the Minimum Guaranteed
     Royalty Payment of $5,000,000 called for in section 3.2 of this Agreement
     and such amount shall be due and payable before any such termination shall
     be deemed effective. In the event that Licensee seeks to terminate this
     Agreement or its exclusivity, Licensee shall not be entitled to the refund
     of any Minimum Guaranteed Payments (including those advanced pursuant to
     Section 3.2 herein, Required Royalty Payments or the Guaranteed License
     Issue Fee that have been paid to date.

     15. In Section 9.4 of the License Agreement, delete "(or, at AccuMed's
discretion, destroy and certify to AccuMed the destruction of)".

     16. With reference to Section 10.4 of the License Agreement, the parties
acknowledge and agree that, upon execution of this Agreement and payment of the
amounts owing to Peter P. Gombrich as outlined in paragraph 5 of the Letter
Agreement, the Letter Agreement will be superseded.

     17. Paragraph 10.5 of the License Agreement shall be modified to reflect
the new addresses listed below:

     AccuMed International, Inc.
     920 North Franklin Street, Suite 402
     Chicago, Illinois 60610
     Attention: Paul F. Lavallee
                Chairman and CEO
     Telephone No.: (312) 642-9200
     Fax No.: (312) 642-3101

                                       7
<PAGE>   8

     Ampersand Medical Corporation
     414 N. Orleans
     Suite 305
     Chicago, IL 60610
     Attention: Peter P. Gombrich, Chairman and CEO
     Telephone Number: (312) 222-9550
     Fax Number: (312) 222- 9580

with a copy to its counsel:

     Janet S. Baer
     Schwartz, Cooper, Greenberger & Krauss
     180 N. LaSalle Street
     Suite 2700
     Chicago, IL 60601
     (312) 346-1300

     18. Section 10.8 is replaced with the following:

     10.8 Succession and Transferability. This Agreement and the License granted
     hereunder shall be binding upon and inure to the benefit of Licensee and
     its successors and assignees permitted hereunder and AccuMed and its
     successors and assignees. Licensee shall not assign this Agreement or the
     License granted hereunder, except to an Affiliated Person, in a sale of
     substantially all of the assets or equity shares of Licensee, or through a
     merger of Licensee into another entity wherein such Affiliated Person,
     purchaser or entity agrees in writing to be bound by this Agreement.

     19. A new paragraph 10.11 is added to the License Agreement which provides
as follows:

     10.11 Mutual Release. The parties hereto mutually release and forever
     discharge each other and their respective agents, officers, directors,
     shareholders, partners, employees, successors, representatives, attorneys
     and assigns, of and from, all actions, agreements, bills, bonds, causes of
     action, claims, controversies, counterclaims, covenants, cross-claims,
     damages, debts, demands, executions, indemnities, judgments, liens,
     promises, suits, third-party actions, filed or unfiled, and sums of money
     whatsoever, in law or in equity, arising out of the disputes which they now
     have or have had to date with respect to the License Agreement, the
     Patents, the Technology and the Copyrighted Works.

                      (Signature Page Immediately Follows)

                                       8
<PAGE>   9

    (Signature Page to Amendment to Patent and Technology License Agreement)

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment to Patent
and Technology License Agreement to be executed as of the day and year first
above written.

         AMPERSAND MEDICAL CORPORATION

         By:   /s/ PETER P. GOMBRICH
               ---------------------
                  Peter P. Gombrich
                  Chairman and CEO

         INPATH, LLC

         By:   /s/ PETER P. GOMBRICH
               ---------------------
                  Peter P. Gombrich
                  Chairman and CEO

         ACCUMED INTERNATIONAL, INC.

         By:  /s/ PAUL F. LAVALLEE
              --------------------
                  Paul F. Lavallee
                  Chairman and CEO

                                       9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]